Oct 11, 2021 · 1h 6m · how-i-built-this
Moderna and Flagship Pioneering: Noubar Afeyan
0:00 / 0:00
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of NPR's 'How I Built This,' host Guy Raz interviews biotech visionary Noubar Afeyan about his journey from surviving the Lebanese Civil War to founding Flagship Pioneering and co-founding Moderna. Afeyan details how his unique institutional approach to parallel entrepreneurship and a decade of mRNA platform engineering enabled the rapid creation of a life-saving COVID-19 vaccine.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Guy holds 34.2% of the talking time here. How this is scored →
Guy as informed peer 4.8 Guest teaching 2.2 Guest disagreement 0.8 Guy pushing back 1.1
speaking balance: gold is Guy, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 42:58 Afeyan rejects the isolated framing of Moderna's risk
Afeyan directly challenges Raz's premise that Moderna was a singular, high-stakes gamble, insisting Raz is viewing the venture in isolation rather than as one of a hundred parallel platform bets.
Hardest push from Guy ▶ 42:25 Raz presses Afeyan on scientific doubt and potential disasterRaz refuses to accept a tidy narrative of inevitable success, repeatedly pushing Afeyan on why they proceeded when the broader scientific community believed mRNA research was folly.
Biggest teaching moment ▶ 48:26 Afeyan explains pre-revenue biotech norms and clinical progressAfeyan corrects Raz's scrutiny of Moderna's large operating losses at IPO, demonstrating that 10-year development cycles are standard in biotech and showing they already had 2,000 clinical patients.
Guy holds their own ▶ 18:50 Raz explains protein separation mechanics accuratelyRaz lays out a precise technical summary of protein chromatography and intact molecular identification, prompting Afeyan to acknowledge that Raz explained the core bioengineering advance accurately.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Guy as informed peer | Guest teaching | Guest disagreement | Guy pushing back | Why |
|---|---|---|---|---|---|---|
| Surviving the Lebanese Civil War and Emigrating to Montreal | 3 | 1 | 0 | 0 | Guy Raz sets a warm, narrative interview tone asking about Noubar Afeyan's childhood during the Lebanese Civil War and his family's relocation to Montreal. Afeyan provides reflective autobiographical accounts with no adversarial tension. | |
| Navigating Higher Education and Biochemical Engineering at MIT | 4 | 2 | 1 | 1 | Raz assumes Afeyan's entrepreneurial ambitions stemmed from his father, which Afeyan gently reframes by crediting a chance encounter with Hewlett-Packard co-founder David Packard. Raz displays historical familiarity with Packard's career. | |
| Rejecting Corporate Safety and Raising Initial Seed Capital | 4 | 2 | 1 | 1 | Raz guides the narrative through Afeyan's decision to forgo a safe VP role at IDEC to raise capital right after the 1987 stock market crash. Afeyan humorously describes his initial fundraising efforts as persistent begging without pushback from either side. | |
| Building and Scaling PerSeptive Biosystems | 6 | 2 | 0 | 0 | Raz attempts a technical explanation of protein separation chromatography and mass spectrometry, earning explicit praise from Afeyan for summarizing it well. Afeyan elaborates on the business trajectory and management dynamics of PerSeptive Biosystems. | |
| The Celera Genomics Venture and the Human Genome Race | 5 | 1 | 0 | 0 | Raz accurately contextualizes the late 1990s race to map the human genome alongside Celera Genomics and Aplera. Afeyan explains their commercial vision of building a Bloomberg terminal for genomics data. | |
| Mid-Episode Break: Transition and Show Identification | 5 | 2 | 0 | 0 | Raz and Afeyan discuss how Flagship Pioneering differs fundamentally from standard venture incubators by institutionalizing startup origination under one roof. Afeyan explains his philosophy of de-romanticizing chaotic startup folklore into systematic methodology. | |
| The Genesis of Moderna and Exploring mRNA Capabilities | 5 | 2 | 1 | 0 | Raz details the early scientific origins of mRNA research and Bob Langer's involvement. Afeyan notes that widespread scientific skepticism persisted until very recently, explaining how Flagship treated cellular biology as programmable software. | |
| Operating Beyond Adjacencies and Managing Portfolio Risk | 6 | 4 | 3 | 5 | Raz presses Afeyan on whether Flagship faced severe internal doubt and risk when pursuing an unproven technology against scientific consensus. Afeyan pushes back against the isolated framing of Moderna, educating Raz on Flagship's portfolio strategy of parallel platform exploration beyond adjacencies. | |
| Mid-Episode Break: Transition to the Vaccine Race | 5 | 4 | 2 | 4 | Raz challenges Moderna's financial standing at its 2018 IPO, noting massive operating losses with zero commercial revenue. Afeyan reframes the metric, pointing out that 10-year development timelines are standard in biotech and highlighting that 2,000 clinical patients had already received mRNA. | |
| The Pandemic Outbreak and Designing mRNA-1273 in Two Days | 5 | 2 | 0 | 0 | Raz chronicles the early days of January 2020 as COVID-19 emerged, asking about Moderna's decision-making timeline. Afeyan details the historic two-day turnaround between receiving the SARS-CoV-2 sequence and finalizing the mRNA-1273 construct. | |
| Personal Grief and Navigating Public Pandemic Scrutiny | 4 | 2 | 1 | 1 | The conversation shifts to the emotional weight of Afeyan losing his father-in-law to COVID-19 early in the pandemic while racing to develop the vaccine. Afeyan addresses media criticism regarding initial Phase 1 disclosures, defending the duty to report material public health data. | |
| Phase 3 Efficacy, Manufacturing at Scale, and Platform Validation | 6 | 3 | 2 | 2 | Raz asks whether the 94% efficacy trial results proved that mRNA could conquer flu, malaria, and HIV. Afeyan makes a sharp scientific distinction between proof and strong suggestion, emphasizing the necessity of scientific skepticism. | |
| The Vision for Preemptive Medicine and Health Security | 5 | 2 | 0 | 0 | Raz concludes with his signature reflection on luck versus hard work across Afeyan's career. Afeyan contextualizes his immigrant drive and offers a nuanced philosophical perspective on luck being outside an operator's actionable control. |
Statements from this episode (16)
Afeyan: Founders cannot raise biotech capital without specifying concrete technology
“The very first business plan I ended up writing to try to claim that we were going to do this didn't specify technology. It literally just said, we're going to develop instruments that kind of address needs in the biotechnology field, and I quickly learned tha…”
Afeyan: Replaced himself as CEO the day after closing $1 million
“So what I decided to do is I kept talking to people until I found a firm to invest with me as the initial CEO, which is what I had been for the whole time, the year and a half before. And the day after we closed the million dollars, I went to them and I said, …”
Afeyan: Celera Genomics was initially conceived as a biological Bloomberg Terminal
“Ultimately, the thing we decided to do was to become a content delivery company modeled after Bloomberg with the Bloomberg terminals, as you may remember. So Bloomberg takes public information, at least dated back then, annotates it, interconnects it, adds som…”
Afeyan: Celera sequenced the genome because the government project was too slow
“We needed to sequence the genome first, and we at first thought maybe the government can, the government's effort at the time would suffice, but it was going fairly slowly, and so we launched a, what It became a competitive effort, although it wasn't fully int…”
Afeyan: Long biotech lifecycles prevent serial entrepreneurship, forcing internal talent creation
“In biotech, these companies have a half-life or a life cycle of, say, 10 years, 15 years. So people don't do one company after another. If they do one company after 1015 years and they succeed, they stop doing it. So you have to create the talent.”
Afeyan: The romantic 'hero founder' startup folklore is largely unnecessary
“There's a lot of folklore in the startup world, which I'd say emphasizes the role of the individual. There's a hero kind of notion that's created, you know, against all odds. And here we were claiming that conceiving, creating, growing companies could be the o…”
Afeyan: Nobody took mRNA research seriously as recently as 2016
“Five years ago, nobody was taking MRNA research seriously”
Afeyan: Flagship started four platform projects alongside Moderna's foundation
“In the exact same year that we Did the foundation laying for what became Moderna. We also started four other projects that were each platforms in their own right, going after different aspects of biomedical opportunity space, each with as big a leap, each with…”
Afeyan: Precision in guessing what works is unimportant when pioneering new fields
“The accuracy with which you have to guess what's going to work Is not at all important. Because we get into these brand new areas, it's wide open to find where value lies, right? Imagine if we waited three, four years as people did, or 10 years in the case of …”
Afeyan: Moderna tested 9-10 vaccines and spent $2B pre-COVID
“We had tested nine, maybe even 10 different human vaccines in every single case showing neutralizing antibodies, and we had also another nine programs that were going after human therapeutics, so it was a fairly broad platform that had already been developed. …”
Afeyan: 2,000 people received Moderna mRNA before COVID-19 trials
“Before a single vaccine for coronavirus that we tested, we had already 2000 people Who had received mRNA from us.”
Afeyan: Moderna designed the mRNA-1273 vaccine sequence in two days
“And to the time when we had the computer-generated sequence of the RNA, that is essentially today mRNA-twelve-seventy-three, was two days.”
Afeyan: Moderna released early vaccine data to satisfy public disclosure obligations
“Well, we indeed, in May, we indeed did come out and say at a very high level that we had some encouraging results, and people attacked us every which way for having said that, because they basically said, well, that's doing science by press release and many ot…”
Afeyan: The NIH, not Moderna, conducted early COVID-19 vaccine clinical trials
“We didn't do the clinical work. They did.”
Afeyan: Moderna scaled from 1,000 to one billion doses in one year
“We could make, you know, a billion doses the first year of production, up from probably making, you know, a thousand doses the year before of anything.”
Afeyan: Early immune interventions may shield against flu, coronavirus, and HIV
“Because I think that we're learning enough about the immune system that if we intervene early enough and broadly enough, we may well create a shield, a protective shield against these hyper variable viruses like influenza, like Corona, like rhinovirus that cau…”